Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001214659-25-010765
Filing Date
2025-07-22
Accepted
2025-07-22 16:31:28
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 19243
  Complete submission text file 0001214659-25-010765.txt   21024
Mailing Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Business Address 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121 858-200-3830
TANG CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001232621 (see all company filings)

EIN.: 461592449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Subject) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91596 | Film No.: 251140634
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)